Nat. Rev. Urol. doi: /nrurol

Slides:

Advertisements

Similar presentations

Evaluating cell lines as tumor models by comparison of genomic profiles Domcke, S. et al. Nat. Commun 4:2126.

Advertisements

Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.

Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.

Pathology 430/827 Bladder cancer Etiology, classification, and diversity David M. Berman, MD, PhD Pathology and Molecular Medicine Queen’s Cancer Research.

Precision Medicine: The Potential for Identifying Personalized Therapies for Patients with Gastro-Esophageal Cancer.

Figure 1 The heterogenous landscape of triple-negative breast cancer

Volume 389, Issue 10087, Pages (June 2017)

Hallett, et al., - Supplementary Figure 1

LUCIE Localised Urothelial Carcinoma Immuno-oncology Evaluation Randomised Phase II trial, evaluating safety and efficacy of a combination therapy of.

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Figure 4 Types of urinary diversion

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer Karthik V. Giridhar, MD, Manish.

Nat. Rev. Urol. doi: /nrurol

سرطان الثدي Breast Cancer

Figure 1 Cellular processes involved in cancer development

Volume 25, Issue 2, Pages (February 2014)

Figure 3 Birt–Hogg–Dubé (BHD) renal tumour histology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Semantic model of the active surveillance (AS) timeline

Volume 199, Issue 5, Pages (May 2018)

Figure 1 Postulated mechanisms of action of PD‑1, PD‑L1 and PD‑L2

Volume 72, Issue 4, Pages (October 2017)

Nat. Rev. Urol. doi: /nrurol

Plots derived from provisional TCGA data from sequencing and expression analyses of invasive breast carcinoma cases. Plots derived from provisional TCGA.

Re: David J. McConkey, Woonyoung Choi, Colin P. N. Dinney

On Molecular Classification of Bladder Cancer: Out of One, Many

Figure 6 Common signalling mechanisms, pathways,

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 2 Schema for the phase II Randomized Observation versus

Figure 1 Differences in bladder cancer between genders

Figure 13 Proposed management of bladder cancer with variant histology

Figure 2 Differences between MC and AC

Figure 3 Algorithm for the determination of the clinical

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Urol. doi: /nrurol

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Urol. doi: /nrurol

Jean-Charles Nault, Peter R. Galle, Jens U. Marquardt

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Key features of gastric cancer subtypes according to The Cancer Genome Atlas (TCGA) Figure 2 | Key features of gastric cancer subtypes according.

Figure 3 Differences in renal cell carcinoma (RCC) between genders

Figure 3 Template for standard pelvic lymphadenectomy

the SNP profile using 26 prostate cancer GWAS risk SNPs

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 3 Examples of gene expression heterogeneity

Figure 2 Frequency and overlap of alterations

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Distribution of intrinsic subtypes among TNBC and distribution of TNBC among basal-like breast cancer. Distribution of intrinsic subtypes among TNBC and.

Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis Xin Luo, MD, Xiao Zang, BS, Lin Yang, MD, Junzhou Huang, PhD,

Nat. Rev. Urol. doi: /nrurol

Volume 25, Issue 2, Pages (February 2014)

Brendon M. Stiles, MD, Mohamed K. Kamel, MD, Sebron W

Nat. Rev. Urol. doi: /nrurol

From One to Many: Further Refinement of Medulloblastoma Subtypes Offers Promise for Personalized Therapy Abhishek Bavle, D. Williams Parsons Cancer.

Nat. Rev. Urol. doi: /nrurol

Figure 4 Algorithm for when to determine PTEN

Fig. 1. FAM83H over-expression is associated with poor prognosis of CC

DO NOT POST #4054 Gene expression Difference (GED) Revealed Immune Function Gene UP- or Down-regulation as Tumor-associated Inflammatory Cell (TAIC) Infiltration.

Presentation transcript:

Nat. Rev. Urol. doi:10.1038/nrurol.2017.30 Figure 2 Schematic representation of intrinsic subtypes of bladder cancer Figure 2 | Schematic representation of intrinsic subtypes of bladder cancer143. Muscle-invasive bladder cancer (MIBC) is a clinically heterogeneous disease. Using whole-genome mRNA expression profiling, several groups have defined molecular subtypes of MIBC reminiscent of those found in breast cancer. Direct comparisons of tumour subtype assignments made by the four groups have shown great similarities. Molecular subtypes of MIBC might have important implications for patient prognosis and response to conventional chemotherapy and targeted agents. Lund, University of Lund; MDA, MD Anderson Cancer Center; SCC, squamous cell carcinoma; TCGA, The Cancer Genome Atlas; UNC, University of North Carolina. Nguyen, D. P. & Thalmann, G. N. (2017) Contemporary update on neoadjuvant therapy for bladder cancer Nat. Rev. Urol. doi:10.1038/nrurol.2017.30